Business
Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development
Veteran gastroenterologist and clinical development leader with deep expertise driving global Phase 2/3 programs across immunology, neurology, and gastrointestinal disease Carlsbad, CA, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company advancing next-generation, once daily, oral PDE4 inhibitor prodrugs for patients with inflammatory and fibrotic diseases, today announced the appointment of James Izanec, M
About this update from Palisade Bio, Inc.
[{"type":"image","alt":"Palisade Bio, Inc.","displaySize":"","headline":null,"caption":"Palisade Bio, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":77,"url":"https://media.zenfs.com/en/globenewswire.com/2a3a6d9c80425bf813c98abfe355e747"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/VBDa4YPveOaoDW8bYlQJUA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/2a3a6d9c80425bf813c98abfe355e747","width":300,"height":77}},"lazy":false},{"type":"text","content":"Veteran gastroenterologist and clinical development leader with deep expertise driving global Phase 2/3 programs across immunology, neurology, and gastrointestinal disease","length":171,"tagName":"p"},{"type":"text","content":"Carlsbad, CA, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company advancing next-generation, once daily, oral PDE4 inhibitor prodrugs for patients with inflammatory and fibrotic diseases, today announced the appointment of James Izanec, MD, AGAF as Vice President, Clinical Development.","length":381,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","className":"","disableSlideshowImg":false,"size":{"original":{"width":167,"height":167,"url":"https://media.zenfs.com/en/globenewswire.com/785125c5159572be39ae0f970790945e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/36XpGm3lYpvxrojBDsyDxQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTIxMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/785125c5159572be39ae0f970790945e","width":167,"height":167}}},{"type":"text","content":"","length":0,"tagName":"p"},{"type":"text","content":"Dr. Izanec is a physician–scientist with over two decades of clinical and drug development leadership spanning immunology, neuroscience, and gastroenterology. He brings extensive experience directing registrational Phase 2 and Phase 3 programs, shaping asset-level development strategies, and guiding cross‑functional execution at leading pharmaceutical organizations including Bristol Myers Squibb and Janssen.","length":411,"tagName":"p"},{"type":"text","content":"Dr. Mitchell Jones, Chief Medical Officer of Palisade Bio, commented, “We are thrilled to welcome Dr. Izanec to Palisade. His leadership of major late‑stage global programs, combin...